StocksFin Logo
Grifols, S.A. country of incorporation
|
|
Mr. Raimon Grifols Roura
|
27,584 employees
NASDAQ | Healthcare | Drug Manufacturers—General
BioMarin Pharmaceutical Inc. country of incorporation
|
|
Mr. Jean-Jacques Bienaime
|
3,045 employees
NASDAQ | Healthcare | Biotechnology
Q222 reported Jun 30, 2022 Reporting Period
$1.54B 14.1% vs. Q221 Revenues Q222
37.46% -12.8% vs. Q221 Gross Profit Margin
5.86% -42.2% vs. Q221 Net Profit Margin
88.81M -79.6% vs. Q221 Free Cash Flow Q222
$0.13 -34% vs. Q221 EPS Q222
Period
Profitable?
Revenue Growth?
Net Profit Growth?
FCF Growth?
OCF Growth?
EPS Growth?
Pays Dividend?
Q222
Q322
Q322 reported Oct 28, 2022 Reporting Period
$505.34M 23.6% vs. Q321 Revenues Q322
76.99% 3.1% vs. Q321 Gross Profit Margin
-1.32% ! 85.3% vs. Q321 Net Profit Margin
121.85M 25.5% vs. Q321 Free Cash Flow Q322
$-0.04 ! 80% vs. Q321 EPS Q322
-
Period
Profitable?
Revenue Growth?
Net Profit Growth?
FCF Growth?
OCF Growth?
EPS Growth?
Pays Dividend?
Q222
Q322
Loading...
Loading...
Loading...
Loading...
Ratios
As of
Dec 31, 2021
Sep 30, 2022
Quick Ratio
0.92
3.25
Current Ratio
1.59
5.15
Cash Ratio
0.19
1.46
Price to Book
1.11
3.44
Price to Sales
1.37
31.13
Price to Earnings
37.02
-591.29